About Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:IDXG
CUSIP69329V10
Phone855-776-6419
Debt
Debt-to-Equity RatioN/A
Current Ratio2.45%
Quick Ratio2.45%
Price-To-Earnings
Trailing P/E Ratio-1.12
Forward P/E Ratio-3.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.90 million
Price / Sales1.59
Cash FlowN/A
Price / CashN/A
Book Value$1.48 per share
Price / Book0.61
Profitability
EPS (Most Recent Fiscal Year)($0.81)
Net Income$-12,210,000.00
Net Margins-76.84%
Return on Equity-37.15%
Return on Assets-24.89%
Miscellaneous
Employees75
Outstanding Shares27,870,000
Interpace Diagnostics Gr (NASDAQ:IDXG) Frequently Asked Questions
What is Interpace Diagnostics Gr's stock symbol?
Interpace Diagnostics Gr trades on the NASDAQ under the ticker symbol "IDXG."
How were Interpace Diagnostics Gr's earnings last quarter?
Interpace Diagnostics Gr (NASDAQ:IDXG) issued its quarterly earnings results on Thursday, August, 10th. The business services provider reported ($0.65) earnings per share (EPS) for the quarter. The business services provider had revenue of $3.86 million for the quarter. Interpace Diagnostics Gr had a negative net margin of 76.84% and a negative return on equity of 37.15%. View Interpace Diagnostics Gr's Earnings History.
What price target have analysts set for IDXG?
3 Wall Street analysts have issued 1-year price objectives for Interpace Diagnostics Gr's stock. Their forecasts range from $3.00 to $4.50. On average, they expect Interpace Diagnostics Gr's share price to reach $3.50 in the next twelve months. View Analyst Ratings for Interpace Diagnostics Gr.
Who are some of Interpace Diagnostics Gr's key competitors?
Some companies that are related to Interpace Diagnostics Gr include Neovasc (NVCN), Arch Therapeutics (ARTH), Presbia (LENS), Cellect Biotechnology (APOP), AIT Therapeutics (AITB), Cytori Therapeutics (CYTX), InVivo Therapeutics (NVIV), Valeritas (VLRX), Alliqua BioMedical (ALQA), Neurometrix (NURO), Amedica (AMDA), Avinger (AVGR), STRATA Skin Sciences (SSKN), TearLab (TEAR) and Lombard Medical Technologies (EVARF).
Who are Interpace Diagnostics Gr's key executives?
Interpace Diagnostics Gr's management team includes the folowing people:
- Mr. Jack E. Stover, Chief Exec. Officer, Pres and Director (Age 65)
- Mr. James E. Early, CFO, Treasurer & Sec. (Age 64)
- Mr. Thomas John Freeburg, Chief Accounting Officer (Age 50)
- Mr. Frank Arena, Sr. VP of Established Relationship Sales & Commercial Operations
- Mr. Gregory Richard, Chief Commercial Officer
Has Interpace Diagnostics Gr been receiving favorable news coverage?
Media stories about IDXG stock have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Interpace Diagnostics Gr earned a media sentiment score of 0.18 on Accern's scale. They also assigned press coverage about the business services provider an impact score of 47.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Interpace Diagnostics Gr?
Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Interpace Diagnostics Gr's stock price today?
One share of IDXG stock can currently be purchased for approximately $0.9099.
How big of a company is Interpace Diagnostics Gr?
Interpace Diagnostics Gr has a market capitalization of $25.34 million and generates $15.90 million in revenue each year. The business services provider earns $-12,210,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Interpace Diagnostics Gr employs 75 workers across the globe.
How can I contact Interpace Diagnostics Gr?
Interpace Diagnostics Gr's mailing address is MORRIS CORPORATE CENTER 1 BUILDING A 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]
MarketBeat Community Rating for Interpace Diagnostics Gr (IDXG)
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Gr and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
Interpace Diagnostics Gr (NASDAQ:IDXG) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Interpace Diagnostics Gr in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 284.66%. The high price target for IDXG is $4.50 and the low price target for IDXG is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Buy | Buy | Buy | Buy |
Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
Ratings Breakdown: | 0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | $3.50 | $3.50 | $5.00 | $5.00 |
Price Target Upside: | 284.66% upside | 218.18% upside | 290.63% upside | 504.23% upside |
Interpace Diagnostics Gr (NASDAQ:IDXG) Consensus Price Target History

Interpace Diagnostics Gr (NASDAQ:IDXG) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Interpace Diagnostics Gr (NASDAQ:IDXG) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Interpace Diagnostics Gr (NASDAQ IDXG) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.70%
Institutional Ownership Percentage: 13.11%
Interpace Diagnostics Gr (NASDAQ IDXG) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
11/25/2014 | Graham G Miao | CFO | Buy | 22,000 | $1.65 | $36,300.00 | | |
11/10/2014 | Nancy Lurker | CEO | Buy | 49,000 | $1.75 | $85,750.00 | | |
11/7/2014 | Gerald R Melillo Jr | Insider | Buy | 5,000 | $1.58 | $7,900.00 | | |
11/7/2014 | Jeffrey Edward Smith | VP | Buy | 200,000 | $1.75 | $350,000.00 | | |
11/6/2014 | Nancy Lurker | CEO | Buy | 57,000 | $1.74 | $99,180.00 | | |
11/5/2014 | Gerald P Belle | Director | Buy | 57,300 | $1.71 | $97,983.00 | | |
11/18/2013 | Gerald Belle | Director | Buy | 20,400 | $5.21 | $106,284.00 | 84,357 | |
(Data available from 1/1/2013 forward)
Interpace Diagnostics Gr (NASDAQ IDXG) News Headlines
Source: |
|
Date | Headline |
---|
 | Interpace Diagnostics Gr (IDXG) Given Average Recommendation of "Strong Buy" by Brokerages www.americanbankingnews.com - April 22 at 3:12 AM |
 | Interpace Diagnostics Gr (IDXG) PT Set at $3.00 by HC Wainwright www.americanbankingnews.com - April 6 at 11:06 AM |
 | Interpace Diagnostics Gr (IDXG) Downgraded to "Strong Sell" at ValuEngine www.americanbankingnews.com - April 3 at 1:52 PM |
 | Active-Investors: Free Research Report as Verisk's Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5% www.finanznachrichten.de - April 2 at 8:30 AM |
 | Free Research Report as Verisk’s Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5% finance.yahoo.com - April 2 at 8:30 AM |
 | Interpace Diagnostics Gr (IDXG) Receives Average Rating of "Strong Buy" from Brokerages www.americanbankingnews.com - March 31 at 3:18 PM |
 | Acupath to promote Interpace thyroid tests seekingalpha.com - March 28 at 5:23 PM |
 | Interpace Diagnostics Gr (IDXG) Given a $3.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - March 28 at 2:04 PM |
 | Interpace Diagnostics Gr (IDXG) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - March 25 at 5:22 PM |
 | Interpace Diagnostics Announces Expansion of LabCorp National Agreement finance.yahoo.com - March 20 at 8:21 AM |
 | Interpace Diagnostics Group (IDXG) PT Set at $3.00 by Maxim Group www.americanbankingnews.com - March 16 at 8:20 PM |
 | Edited Transcript of IDXG earnings conference call or presentation 15-Mar-18 8:30pm GMT finance.yahoo.com - March 16 at 6:33 PM |
 | Interpace Diagnostics Group's (IDXG) "Buy" Rating Reiterated at HC Wainwright www.americanbankingnews.com - March 16 at 1:48 PM |
 | Interpace Diagnostics Announces Timing of Earnings Release and ... - GlobeNewswire (press release) globenewswire.com - March 15 at 8:11 AM |
 | Worldpay (WP) and Interpace Diagnostics Group (IDXG) Critical Contrast www.americanbankingnews.com - March 12 at 9:13 PM |
 | Interpace Diagnostics Announces Additional Coverage of Thyroid Tests - GlobeNewswire (press release) globenewswire.com - March 10 at 8:17 AM |
 | New Research Coverage Highlights Great Western, Acadia Realty Trust, Interpace Diagnostics Group, Abercrombie & Fitch, United Rentals, and ZIOPHARM Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018 finance.yahoo.com - March 9 at 8:14 AM |
 | Interpace Diagnostics Group (IDXG) Research Coverage Started at HC Wainwright www.americanbankingnews.com - March 8 at 11:40 PM |
 | HC Wainwright Takes Bullish Stance On Interpace Diagnostics ... - Benzinga www.benzinga.com - March 8 at 6:52 PM |
 | Interpace Diagnostics Announces Additional Coverage of Thyroid Tests finance.yahoo.com - March 8 at 6:52 PM |
 | Interpace Diagnostics Announces Additional Coverage of Thyroid Tests - Nasdaq www.nasdaq.com - March 8 at 8:16 AM |
 | Interpace Diagnostics (IDXG) Announces Additional Coverage of Thyroid Tests - StreetInsider.com www.streetinsider.com - March 8 at 8:16 AM |
 | Comparing Interpace Diagnostics Group (IDXG) and Nelnet (NNI) www.americanbankingnews.com - March 5 at 1:52 PM |
 | Interpace Diagnostics' (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid Tests www.streetinsider.com - February 27 at 5:58 PM |
 | Interpace Diagnostics' (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid Tests - StreetInsider.com www.streetinsider.com - February 27 at 8:14 AM |
 | Interpace Diagnostics' CEO Interviewed on The RedChip Money ... - GlobeNewswire (press release) globenewswire.com - February 23 at 8:16 AM |
 | Interpace Diagnostics Group (IDXG) Research Coverage Started at Laidlaw www.americanbankingnews.com - February 22 at 3:02 PM |
 | Interpace Diagnostics Group Inc (IDXG) PT Lowered to $3 at Maxim Group - StreetInsider.com www.streetinsider.com - February 16 at 8:14 AM |
 | Interpace Diagnostics Group (IDXG) Given a $3.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - February 14 at 10:40 PM |
 | Interpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung Assays finance.yahoo.com - February 12 at 9:07 AM |
 | Analyzing MAXIMUS (MMS) & Interpace Diagnostics Group (IDXG) www.americanbankingnews.com - January 26 at 9:06 AM |
 | Interpace Diagnostics to Present at NobleCon14 on January 29 finance.yahoo.com - January 25 at 9:05 AM |
 | Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers - GlobeNewswire (press release) globenewswire.com - January 8 at 4:00 PM |
 | What Does Interpace Diagnostics Group Inc’s (NASDAQ:IDXG) Share Price Indicate? finance.yahoo.com - January 6 at 6:30 AM |
 | Comparing Interpace Diagnostics Group (IDXG) & Lifelock (LOCK) www.americanbankingnews.com - December 28 at 7:34 PM |
 | Interpace Diagnostics Announces Agreement with ARUP Laboratories - GlobeNewswire (press release) globenewswire.com - December 19 at 3:53 PM |
 | Interpace Diagnostics Group (IDXG) and Willdan Group (WLDN) Financial Survey www.americanbankingnews.com - December 19 at 1:26 AM |
 | Interpace Diagnostics Group, Inc. :IDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017 finance.yahoo.com - December 18 at 11:37 AM |
 | Contrasting Interpace Diagnostics Group (IDXG) & Ritchie Bros. Auctioneers (RBA) www.americanbankingnews.com - November 24 at 3:28 AM |
 | Head-To-Head Analysis: Unifirst Corporation (UNF) versus Interpace Diagnostics Group (IDXG) www.americanbankingnews.com - November 18 at 3:37 AM |
 | BRIEF-Interpace Diagnostics says New York State Department Of Health approved its TERT service offering www.reuters.com - November 17 at 6:40 PM |
 | Interpace Diagnostics Announces New York State Approval of New Product finance.yahoo.com - November 17 at 5:36 AM |
 | Interpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim Group www.americanbankingnews.com - November 14 at 1:14 PM |
 | BRIEF-Interpace Diagnostics says Q3 sales up 27 pct www.reuters.com - November 14 at 12:51 AM |
 | Edited Transcript of IDXG earnings conference call or presentation 13-Nov-17 1:30pm GMT finance.yahoo.com - November 14 at 12:51 AM |
 | Interpace Diagnostics Group's (IDXG) CEO Jack Stover on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - November 13 at 7:49 PM |
 | Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments finance.yahoo.com - November 13 at 7:49 PM |
 | Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017 finance.yahoo.com - November 11 at 11:14 AM |
 | Ituran Location and Control (ITRN) & Interpace Diagnostics Group (IDXG) Financial Contrast www.americanbankingnews.com - November 7 at 9:36 PM |
 | Recent VRSK News www.bloomberg.com - November 2 at 1:52 AM |
Interpace Diagnostics Gr (NASDAQ:IDXG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Interpace Diagnostics Gr (NASDAQ:IDXG) Income Statement, Balance Sheet and Cash Flow Statement
Interpace Diagnostics Gr (NASDAQ IDXG) Stock Chart for Sunday, April, 22, 2018
Loading chart…